Tirofiban Hydrochloride Patent Expiration
Tirofiban Hydrochloride is Used for reducing thrombotic coronary events in patients with acute coronary syndrome. It was first introduced by Medicure International Inc
Tirofiban Hydrochloride Patents
Given below is the list of patents protecting Tirofiban Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aggrastat | US6770660 | Method for inhibiting platelet aggregation |
May 01, 2023
(Expired) | Medicure |
| Aggrastat | US6136794 | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
Jan 29, 2019
(Expired) | Medicure |
| Aggrastat | US5978698 | Angioplasty procedure using nonionic contrast media |
Oct 08, 2017
(Expired) | Medicure |
| Aggrastat | US5733919 | Compositions for inhibiting platelet aggregation |
Oct 23, 2016
(Expired) | Medicure |
| Aggrastat | US5733919 | Compositions for inhibiting platelet aggregation |
Oct 23, 2016
(Expired) | Medicure |
| Aggrastat | US5965581 | Compositions for inhibiting platelet aggregation |
Oct 23, 2016
(Expired) | Medicure |
| Aggrastat | US5972967 | Compositions for inhibiting platelet aggregation |
Oct 23, 2016
(Expired) | Medicure |
Tirofiban Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Tirofiban Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Tirofiban Hydrochloride. The first generic version for Tirofiban Hydrochloride was by Gland Pharma Ltd and was approved on Apr 8, 2021. And the latest generic version is by Nexus Pharmaceuticals Llc and was approved on Jul 24, 2023.
Given below is the list of companies who have filed for Tirofiban Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 2 different strengths of generic version for Tirofiban Hydrochloride. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) | solution | Prescription | INTRAVENOUS | AP | May 1, 2023 |
| EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) | solution | Prescription | INTRAVENOUS | AP | May 1, 2023 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
2. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Tirofiban Hydrochloride. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 8, 2021 |
3. NEXUS
Nexus Pharmaceuticals Llc has filed for 2 different strengths of generic version for Tirofiban Hydrochloride. Given below are the details of the strengths of this generic introduced by Nexus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) | solution | Prescription | INTRAVENOUS | AP | Feb 7, 2023 |
| EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 24, 2023 |
Manufacturing Plant Locations New
Nexus's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Nexus as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||||||||||